Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Key Highlights
- ➤Halozyme expands argenx collaboration to two additional exclusive ENHANZE targets
- ➤argenx’s exclusive ENHANZE access increases from six to eight targets
- ➤Halozyme eligible for milestone payments and royalties on net product sales
Expert Statements
Helen Torley, President and Chief Executive Officer of Halozyme
“We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo.”
Helen Torley, President and Chief Executive Officer of Halozyme
“The addition of two new exclusive targets further validates the value and versatility of ENHANZE as the leading platform for rapid, large-volume subcutaneous delivery.”
Helen Torley, President and Chief Executive Officer of Halozyme
“As more companies seek to focus on patient convenience, reducing treatment burden and expanding access to important therapies, ENHANZE continues to be the technology of choice.”
Helen Torley, President and Chief Executive Officer of Halozyme
“This expanded agreement strengthens our growing portfolio of partnered programs and reinforces the significant long-term opportunity for ENHANZE across a broad range of therapeutic areas.”
Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx
“Our partnership with Halozyme shows what co-creation can do for patients.”
Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx
“Together, we brought VYVGART Hytrulo to people living with MG and CIDP, which gave patients a subcutaneous option that fits more easily into their lives.”
Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx
“Expanding to two more targets lets us bring that same focus on patient experience to more of our pipeline as we build a broader immunology portfolio.”
Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx
“We’re proud to keep building on a partnership, rooted in shared ambition and scientific rigor.”
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology PR Newswire
Expanded agreement increases argenx's exclusive access to ENHANZE(®) from six to eight targets
Get started
Create a free account to read the full story.